Trial Watch No. 16
The Most Concentrated Phase 3 Push in Modern Pharma
Where conviction is building in clinical development, in real time. AstraZeneca opened four mega-scale Phase 3s totaling 17,200 patients in a single two-week window, in vivo CAR-T crossed into autoimmune disease, and Regeneron's Factor XI franchise expanded to a fourth indication.
Summary Layer
The second half of August 2026 is dominated by AstraZeneca. In a single two-week window, AZ opened four mega-scale Phase 3s totaling 17,200 patients: Elevate-CKD (7,000 pts, elecoglipron for renal + mortality outcomes in CKD), Elevate-HF (6,950 pts, elecoglipron in HFpEF/HFmrEF), SELENE 1 (2,500 pts, AZD6234 obesity flagship), and DURGA-6 (750 pts, AZD0120 dual BCMA/CD19 CAR-T vs. autologous stem cell transplant in newly diagnosed multiple myeloma). This is the most concentrated single-sponsor Phase 3 push in modern pharma history.
In vivo CAR-T crosses into autoimmune disease. Myeloid Therapeutics opened CRT-402; the first Phase 1/2 of an in vivo CD19-targeted CAR-T therapy in refractory lupus, systemic sclerosis, and myositis. Ex vivo CAR-T requires bespoke manufacturing per patient; in vivo delivery is off-the-shelf. If safe, it removes the manufacturing bottleneck that has kept autoimmune CAR-T bespoke and academic.
Regeneron's Factor XI franchise expands to a fourth indication. ROXI-PEAK (REGN7508 + REGN9933 for PICC-line-associated VTE prophylaxis, 1,908 pts) joins ROXI-EVEREST (AF, Ed 14), ROXI-PALISADE (PAD, Ed 10), and ROXI-CAT-II (cancer VTE, Ed 12). Now over 26,000 patients across four indications from a single-antibody franchise. 15 high-signal trials across oncology, cardiometabolic, immunology, respiratory, and advanced modalities.
Therapeutic Areas Covered
Oncology
5 trialsDURGA-6 · AZD0120 Dual BCMA/CD19 CAR-T vs. ASCT in Transplant-Eligible Newly Diagnosed Multiple Myeloma
Phase 3 · Oncology; NDMM (CAR-T vs. transplant)
Timeline
Start August 25, 2026; Primary completion October 2028
Mechanism
AZD0120 is an autologous dual-targeting CAR-T therapy directed against BCMA and CD19 in a single construct. Compared head-to-head against autologous stem cell transplant (ASCT) as consolidation in transplant-eligible NDMM. AZ inherited the dual CAR-T platform via its 2023 Neogene Therapeutics acquisition.
Why It Matters
ASCT has been the transplant-eligible NDMM standard for 30+ years. This is the first randomized Phase 3 testing whether a dual-target CAR-T can replace transplant altogether. If AZD0120 wins on efficacy or MRD, ASCT becomes optional and CAR-T becomes the front-line consolidation of choice; a 30-year practice inversion. AZ becomes a first-mover Big Pharma challenger to Legend/J&J and BMS/2Seventy in CAR-T MM.
DeLLphi-315 · Subcutaneous vs. Intravenous Tarlatamab in Relapsed Extensive-Stage Small Cell Lung Cancer
Phase 3 · Oncology; SC vs IV tarlatamab in ES-SCLC
Timeline
Start August 31, 2026; Primary completion September 2027
Mechanism
Head-to-head Phase 3 of subcutaneous vs. intravenous tarlatamab (Imdelltra, Amgen's DLL3xCD3 bispecific approved 2024 for R/R ES-SCLC). Establishes bioequivalence, safety, and efficacy of the SC formulation.
Why It Matters
Cell-engager therapy follows the subcutaneous playbook that transformed oncology (SC pembrolizumab, SC daratumumab, SC nivolumab, SC rituximab). If SC tarlatamab hits, it moves ES-SCLC treatment from hospital infusion suites to outpatient injection; dramatically reducing cost, chair time, and access barriers. Tarlatamab is the first BiTE to reach solid tumor approval; SC conversion is the next step in mainstreaming BiTE therapy.
Cadonilimab + Chemotherapy vs. Chemo ± Nivolumab in First-Line HER2-Negative Gastric or GEJ Adenocarcinoma
Phase 3 · Oncology; first-line gastric/GEJ
Timeline
Start August 20, 2026; Primary completion August 2029
Mechanism
Cadonilimab (AK104, Akeso's approved PD-1/CTLA-4 bispecific antibody) combined with CAPOX chemotherapy; tested against the same chemo backbone with or without nivolumab; in previously untreated, HER2-negative unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Why It Matters
First randomized head-to-head between a PD-1/CTLA-4 bispecific and a PD-1 monotherapy backbone in front-line gastric cancer. Cadonilimab has repeatedly hit in Chinese oncology (cervical, gastric, HCC); this multi-regional Phase 3 tests whether it can displace nivolumab (currently approved with CAPOX for PD-L1+ front-line gastric) globally.
Verified sources
Daratumumab on Modified Augmented BFM Backbone in Newly Diagnosed T-Lymphoblastic Leukemia and Lymphoma
Phase 2/3 · Oncology; pediatric T-ALL/T-LL (COG)
Timeline
Start August 28, 2026; Primary completion September 2035
Mechanism
Daratumumab (Janssen's approved anti-CD38 antibody) added to a modified Augmented Berlin-Frankfurt-Münster (aBFM) chemotherapy backbone in newly diagnosed pediatric T-ALL and T-lymphoblastic lymphoma. CD38 is highly expressed on T-lymphoblasts.
Why It Matters
One of the largest pediatric leukemia trials in a decade. Pediatric T-ALL relapse remains difficult to salvage. Daratumumab has proven survival benefits in multiple myeloma; adding it to front-line pediatric T-ALL tests whether CD38 targeting can meaningfully reduce relapse in the pediatric T-cell lineage; a first-front-line pediatric CD38 application at scale.
Verified sources
PIRAMID · Pirtobrutinib + R-CHOP vs. R-CHOP in Previously Untreated Richter Transformation
Phase 3 · Oncology; Richter transformation (first pivotal)
Timeline
Start August 31, 2026; Primary completion October 2035
Mechanism
Pirtobrutinib (Lilly's non-covalent BTK inhibitor, approved 2023 for R/R CLL/SLL after covalent BTKi + BCL2i) added to R-CHOP in previously untreated Richter transformation; CLL/SLL that has evolved into aggressive DLBCL.
Why It Matters
Richter transformation is among the deadliest events in CLL; median survival remains under 12 months on R-CHOP alone. No dedicated Phase 3 has been completed in this indication. PIRAMID is the first randomized Phase 3 to test whether adding a non-covalent BTK inhibitor to standard immunochemo alters that trajectory. First Phase 3 to define a standard of care for Richter transformation.
Verified sources
Cardiometabolic
5 trialsElevate-CKD · Elecoglipron for Renal Outcomes and Mortality in Chronic Kidney Disease
Phase 3 · Cardiometabolic; CKD outcomes (mega)
Timeline
Start August 28, 2026; Primary completion October 2030
Mechanism
Elecoglipron is AstraZeneca's oral small-molecule GLP-1 receptor agonist (in-licensed from Eccogene, 2023). Tested at scale in chronic kidney disease patients for hard renal endpoints; dialysis, transplant, kidney death; plus all-cause mortality.
Why It Matters
First oral small-molecule GLP-1 Phase 3 in CKD outcomes. Semaglutide (FLOW trial) showed injectable GLP-1 slowed CKD progression. Elecoglipron tests whether an oral small-molecule can replicate that outcome; with dramatically lower cost of goods, simpler distribution, and better patient uptake. 7,000-pt outcomes trial at 426 sites is one of the largest single CKD Phase 3s ever registered.
Verified sources
Elevate-HF · Elecoglipron for Cardiovascular Outcomes in HFpEF and HFmrEF
Phase 3 · Cardiometabolic; HFpEF/HFmrEF outcomes (mega)
Timeline
Start August 28, 2026; Primary completion September 2029
Mechanism
Companion mega-trial to Elevate-CKD: same oral GLP-1 (elecoglipron), tested for CV outcomes in heart failure with preserved ejection fraction (HFpEF) and mildly reduced ejection fraction (HFmrEF).
Why It Matters
HFpEF has been notoriously hard to drug. Semaglutide's STEP-HFpEF program made GLP-1 a validated HFpEF option; now oral small-molecule GLP-1 tests whether the same benefit extends to non-injectable delivery. Combined with Elevate-CKD, AZ is running a nearly 14,000-patient GLP-1 outcomes program in a single 2-week Phase 3 launch; the most concentrated oral GLP-1 outcomes program in pharma history.
SELENE 1 · AZD6234 in Obesity or Overweight With Weight-Related Comorbidity (No T2D)
Phase 3 · Cardiometabolic; obesity flagship
Timeline
Start August 19, 2026; Primary completion August 2028
Mechanism
AZD6234 is AstraZeneca's long-acting amylin analog for obesity; the SELENE program flagship. SELENE 1 covers obesity without T2D (2,500 pts), SELENE 2 covers obesity + T2D (1,500 pts, also opened this window), and SELENE 3 tests AZD6234 as add-on to incretin-based therapies (500 pts).
Why It Matters
Amylin is the mechanism behind CagriSema (Novo's semaglutide + cagrilintide combination). AZ's SELENE program bets that amylin alone; or as an add-on; can compete with GLP-1/amylin combinations while avoiding the GI tolerability profile. Three parallel Phase 3s (SELENE 1/2/3) totaling 4,500 patients across sponsors #10 in the obesity race (AbbVie Ed 15) and now AZ scaling.
Verified sources
ROXI-PEAK · REGN7508 + REGN9933 for VTE Prophylaxis in Peripherally Inserted Central Catheter Patients
Phase 3 · Cardiometabolic; PICC-associated VTE prophylaxis
Timeline
Start August 20, 2026; Primary completion June 2029
Mechanism
Master protocol testing REGN7508 (Regeneron's anti-FXI mAb; same molecule as ROXI-EVEREST, ROXI-PALISADE, ROXI-CAT-II) plus REGN9933 (companion anti-FXI asset) for prophylaxis of venous thromboembolism in patients with peripherally inserted central catheters (PICCs).
Why It Matters
Fourth ROXI trial. Regeneron's FXI antibody program now covers atrial fibrillation, peripheral arterial disease, cancer-associated VTE, and PICC-associated VTE; totaling over 26,000 patients across four indications in four consecutive editions. Catheter-associated VTE is a $1B+ subsegment historically served by DOACs or LMWH; a monoclonal antibody alternative reduces bleeding risk without daily dosing.
Verified sources
Early Pelacarsen Initiation in US Patients With Elevated Lp(a) and Recent Acute Coronary Syndrome
Phase 3 · Cardiometabolic; Lp(a) reduction in ACS
Timeline
Start August 31, 2026; Primary completion December 2028
Mechanism
Pelacarsen (TQJ230) is Novartis's antisense oligonucleotide targeting hepatic apolipoprotein(a) synthesis; the first Lp(a)-lowering therapy in late-stage clinical development. This Phase 3 tests early post-ACS initiation for effects on coronary plaque and safety in elevated-Lp(a) patients.
Why It Matters
Lp(a) has been the "missing" lipid risk factor; proven to drive atherosclerotic disease genetically, but historically undruggable. Pelacarsen leads a class also including olpasiran (Amgen) and lepodisiran (Lilly). Early initiation post-ACS tests whether Lp(a) lowering shifts plaque biology fast enough to matter for secondary prevention; the highest-signal near-term readout for the Lp(a) category.
Verified sources
Immunology & Respiratory
4 trialsTilrekimig Monotherapy Ph3 vs. Dupilumab in Adult and Adolescent Moderate-to-Severe Atopic Dermatitis
Phase 3 · Immunology; head-to-head vs. Dupilumab in AD
Timeline
Start August 19, 2026; Primary completion August 2028
Mechanism
Head-to-head monotherapy Phase 3 of Pfizer's tilrekimig vs. Sanofi/Regeneron's dupilumab (Dupixent) in mod-severe AD (patients ≥12 years old). 52-week maintenance period included.
Why It Matters
Direct head-to-head vs. the $10B+ Dupixent franchise. Pfizer's Edition 15 tilrekimig Phase 3 was combination therapy; this is monotherapy vs. Dupixent. No more placebo comparators; the AD field has entered active-controlled combat. If tilrekimig meets or beats Dupixent, Sanofi/Regeneron faces its first serious biologic challenger in AD after five years of unchallenged franchise growth.
Verified sources
PERSIST COPD-1 · Felcorekibart (GSK5784283) in Moderate to Very Severe COPD
Phase 3 · Respiratory; COPD (GSK PERSIST)
Timeline
Start August 31, 2026; Primary completion July 2029
Mechanism
Felcorekibart (GSK5784283) is GSK's novel biologic for Type 2 inflammatory diseases. GSK opened six parallel Phase 3s on 8/31 across COPD (PERSIST COPD-1/2, 1,248 pts total), asthma (PERSIST ASTHMA-1/2, 884 pts total), and chronic rhinosinusitis with nasal polyps (PERSIST CRSwNP-1/2, 436 pts total).
Why It Matters
Six parallel Phase 3s across three respiratory indications on the same day for a single asset; one of the fastest and broadest respiratory Phase 3 pipelines opened in modern pharma. GSK is betting felcorekibart is class-agnostic across Type 2 inflammatory respiratory disease, positioning against Dupixent (approved in AD, asthma, CRSwNP, EoE) and tezepelumab across the respiratory Type 2 category.
Verified sources
Upadacitinib in Pediatric Severe Alopecia Areata
Phase 3 · Immunology; pediatric alopecia areata
Timeline
Start August 20, 2026; Primary completion March 2032
Mechanism
Upadacitinib (Rinvoq, AbbVie's JAK1-selective inhibitor, approved in RA, PsA, AD, UC, Crohn's, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and giant cell arteritis) tested in pediatric severe alopecia areata.
Why It Matters
AbbVie extends the Rinvoq label into pediatric AA; a growing dermatology franchise fight after baricitinib (Olumiant) got the first AA approval in 2022 and ritlecitinib (Litfulo) followed for ages 12+. AbbVie's pediatric strategy positions Rinvoq as the go-to JAK for pediatric autoimmune indications across dermatology, gastroenterology, and rheumatology; reinforcing a $10B+ franchise's next decade.
Verified sources
FIBRONEER-ACT · Nerandomilast in Fibrosing Interstitial Lung Disease at Risk for Progression
Phase 3 · Immunology; fibrosing interstitial lung disease
Timeline
Start August 28, 2026; Primary completion December 2028
Mechanism
Nerandomilast (BI 1015550) is BI's oral, preferential PDE4B inhibitor; the succession asset to nintedanib (Ofev) in fibrosing lung disease. FIBRONEER-ACT extends the FIBRONEER program to progressive fibrosing ILD at risk for progression.
Why It Matters
Nerandomilast has already hit primary endpoints in IPF (FIBRONEER-IPF) and progressive fibrosing ILD (FIBRONEER-ILD). FIBRONEER-ACT targets the at-risk-for-progression population before full disease onset; establishing whether nerandomilast can move the antifibrotic use case earlier in the disease course. If positive, it repositions the antifibrotic category from "slow decline in symptomatic disease" to "prevent decline in at-risk disease."
Verified sources
Advanced Modalities
1 trialCRT-402 · In Vivo CD19-Targeted CAR-T Therapy in Refractory Lupus, Systemic Sclerosis, and Myositis
Phase 1/2 · Adv. Modalities; in vivo CAR-T for autoimmune
Timeline
Start August 24, 2026; Primary completion December 2028
Mechanism
CRT-402 is Myeloid Therapeutics' in vivo CD19-targeted CAR-T therapy; delivered as an off-the-shelf infusion that reprograms endogenous T cells to target CD19+ B cells. Tested in systemic lupus erythematosus, systemic scleroderma, and myositis.
Why It Matters
Ex vivo CD19 CAR-T (Kymriah, Yescarta, Breyanzi) has shown remarkable durability in autoimmune disease when tried off-label; but requires bespoke per-patient manufacturing, apheresis, lymphodepletion, and multi-week wait. In vivo CAR-T removes all of it: single infusion, off-the-shelf. First-in-human Phase 1/2 for in vivo CAR-T in autoimmune. If safe and effective, it scales autoimmune CAR-T from bespoke academic to standard biotech logistics; a fundamental modality inflection.
Signal Convergence
Five patterns across the August 16 to 31 window
1. AstraZeneca runs the most concentrated Phase 3 launch in modern pharma
Four AZ mega-Phase 3s in a single 2-week window: Elevate-CKD (7,000 pts), Elevate-HF (6,950 pts), SELENE 1 (2,500 pts), and DURGA-6 (750 pts CAR-T); combined 17,200 patients across CKD, HF, obesity, and MM. Add SELENE 2 (1,500 pts, T2D + obesity) and SELENE 3 (500 pts, add-on to incretins) launching in the same window, and the total exceeds 19,000 patients across six Phase 3s from one sponsor.
2. In vivo CAR-T crosses into autoimmune disease
Myeloid Therapeutics' CRT-402 tests off-the-shelf infusible CD19 CAR-T in lupus, scleroderma, and myositis. Ex vivo autoimmune CAR-T works but requires bespoke manufacturing per patient; in vivo delivery is a single infusion. If safe, autoimmune CAR-T scales from bespoke academic to standard biotech logistics.
3. Regeneron's FXI franchise crosses 26,000 patients across four indications
ROXI-PEAK (1,908 pts in PICC-VTE prophylaxis) is the fourth ROXI trial, joining ROXI-EVEREST (AF, 15,364 pts), ROXI-PALISADE (PAD, 7,050 pts), and ROXI-CAT-II (cancer VTE, 1,600 pts). Single-antibody franchise dominance at a scale without precedent.
4. Head-to-head Phase 3s become the immunology norm
Pfizer's Tilrekimig monotherapy Ph3 head-to-head vs. Dupixent (1,375 pts). No placebo; direct combat for the $10B+ AD franchise. Same window: AstraZeneca's DURGA-6 CAR-T vs. transplant. The era of placebo-controlled biologic Phase 3s in mature immunology and oncology categories is closing.
5. Cell-engager therapy follows the subcutaneous playbook
Amgen's DeLLphi-315 tests SC vs. IV tarlatamab (Imdelltra) in ES-SCLC; moving the first solid tumor-approved BiTE from infusion suite to outpatient injection. SC conversion has already transformed oncology (SC pembrolizumab, SC daratumumab, SC nivolumab, SC rituximab); BiTEs are the next class to make the transition.
Underlying truth: the summer Phase 3 launch pace hasn't slowed; it has intensified. Editions 14 to 16 have delivered mega-scale Phase 3s in AF (15,364 pts), obesity extension (3,200 pts), CKD (7,000 pts), HF (6,950 pts), and obesity flagship (2,500 pts). Pharma is committing capital to definitive readouts at a rate that will fundamentally reshape multiple categories in 2028 to 2030.
Continue Tracking
Trial Watch is Kitsa's clinical intelligence layer. Edition 17 (September 1 to 15, 2026) drops on September 15.
On Verification
Every trial in this edition is anchored to clean, direct, and user-useful source links. Generic sponsor homepages, broad trial search portals, cross registry links, and weak source notes have been removed. The remaining sources point to exact ClinicalTrials.gov records, exact sponsor or institutional trial pages, or exact program sources that clearly support the same drug, indication, and trial context.
About Trial Watch
Trial Watch is Kitsa's twice-monthly U.S. clinical intelligence briefing. It captures high-signal clinical trial events and interprets where science, capital, and strategy are converging.
Keep exploring
Recommended next
- Blog
11 Early-Phase Trials and Design Frameworks to Reduce Design Risk
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
- Blog
4 AI Misconceptions in Clinical Trials You Cannot Afford to Ignore
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
- Blog
7 Questions to Ask Before Choosing an AI Patient Screening Solution
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
- Glossary
Accelerated Approval
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.